UGI Corporation (UGI - Free Report) delivered second-quarter fiscal 2019 adjusted earnings of $1.43 per share, which missed the Zacks Consensus Estimate of $1.58 by 9.49%. The bottom line declined 15.4% from the prior-year quarter’s figure of $1.69.
Excluding one-time items, the company generated GAAP earnings of $1.38 in the reported quarter compared with the year-ago quarter’s figure of $1.57.
Revenues of $2,606 million in the quarter surpassed the Zacks Consensus Estimate of $2,591 million by 0.57%. However, the top line declined 7.3% from the year-ago quarter’s figure of $2,812 million.
Total operating income amounted to $538.8 million compared with $591 million in the year-ago quarter.
Total interest expenses amounted to $61 million, up 5% from the prior-year quarter’s tally.
Warmer-than-normal weather during the critical heating months of January and February led to decline in retail volume in AmeriGas,UGI International and Midstream & Marketing operations.
The company reaffirmed fiscal 2019 EPS guidance in the range of $2.40-$2.60.
UGI currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
MDU Resources Group Inc (MDU - Free Report) delivered first-quarter 2019 operating earnings of 21 cents per share, which missed the Zacks Consensus Estimate of 24 cents by 12.5%.
ONE Gas, Inc (OGS - Free Report) generated first-quarter 2019 operating earnings of $1.76 per share, which beat the Zacks Consensus Estimate of $1.73 by 1.7%.
ONEOK Inc (OKE - Free Report) came up with first-quarter 2019 operating earnings of 81 cents per share, which beat the Zacks Consensus Estimate of 73 cents by 10.96%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>